BI in cancer antibody discovery deal with Oxford BioTherapeutics
Executive Summary
UK oncology drug and companion diagnostic developer Oxford BioTherapeutics Ltd. (OBT) has licensed Boehringer Ingelheim GMBH exclusive rights to develop and market its cancer antibodies.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
- Molecular Diversity
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice